Phase I de-escalation RCT in 24 adult outpatients with mild-moderate COVID-19: no dose-limiting toxicity occurred with molnupiravir 800 mg plus nirmatrelvir/ritonavir versus standard of care, and no grade 3 or higher adverse events were reported.
RCTn = 24
Khoo et al. A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection